Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) is a contract development and manufacturing organization (CDMO) specializing in sterile and non-sterile dosage forms for the pharmaceutical and biotechnology industries. The company offers end-to-end services that span formulation development, clinical trial manufacturing and full commercial production. Operating from its FDA-registered, cGMP-compliant facility in Turners Falls, Massachusetts, Pharma-Bio Serv performs aseptic vial and syringe filling, lyophilization, secondary packaging and cold-chain distribution for small-molecule and biologic drug candidates.
Key business activities include analytical method development and validation, sterile filling and finishing, packaging design and regulatory support. Pharma-Bio Serv’s in-house laboratories conduct release testing, stability studies and quality control analyses in accordance with current good manufacturing practices. This integrated model allows clients to streamline technology transfer and scale up processes from early-stage trials through post-approval commercial supply, while maintaining rigorous oversight of documentation, batch records and compliance.
Founded in the early 2000s by a team of pharmaceutical scientists, Pharma-Bio Serv has grown alongside emerging biotech innovators to serve customers throughout North America and Europe. The company established its first commercial fill-finish line in 2008 and expanded capacity in 2015 with the addition of a second lyophilizer and high-capacity sterile fill suite. Its turnkey solutions cater to orphan drugs, vaccines and specialty injectables, and it has supported numerous IND and NDA submissions for partners advancing both novel therapies and reformulated products.
Leadership is headed by President and Chief Executive Officer John D. Anderson, whose three decades of industry experience include senior operations roles at major pharmaceutical firms. Supported by a seasoned management team and a multidisciplinary board of directors, Pharma-Bio Serv emphasizes quality assurance, regulatory compliance and customer collaboration. The company continues to bolster its capabilities through ongoing investments in facility upgrades, process automation and expanded cold-chain logistics to meet evolving market needs.
AI Generated. May Contain Errors.
